Articles Referencing OPTR
Mid-Afternoon Market Update: Optimer Falls as Halozyme Rockets Upwards
5/16/2013, 3:35 pm from Benzinga in Investing, Commodities, Economy, International
Toward the end of trading Thursday, the Dow was down 0.10
percent to 15,259.91, while the NASDAQ rose 0.13 percent to
3,476.15. The S&P traded down, falling 0.23 percent to
1,654.47. ... Read >>
Wider-than-Expected Loss at Optimer - Analyst Blog
5/10/2013, 12:23 pm from Zacks.com in Investing, Business, Stocks
Optimer Pharmaceuticals Inc. 's ( OPTR ) first quarter
2013 net loss (excluding special items) of 65 cents per share was
wider than the Zacks Consensus Estimate of a loss of 42 cents... Read >>
Optimer's Dificid Cleared Down Under - Analyst Blog
5/1/2013, 6:28 pm from Zacks.com in Investing, Business, Stocks
Optimer Pharmaceuticals ( OPTR ) received
encouraging news recently when the Australian regulatory body
(Australian Therapeutic Goods Administration) cleared its drug
Dificid (fidaxomicin).... Read >>
1Q Earnings Beat at Cubist Pharma - Analyst Blog
4/19/2013, 10:14 am from Zacks.com in Investing, Business, Earnings, Stocks
Cubist Pharmaceuticals Inc. 's ( CBST ) first-quarter
2013 earnings (excluding special items) of 34 cents per share beat
the Zacks Consensus Estimate by a penny. Earnings were however
short... Read >>
Weekly CEO Sells Highlight: Optimer Pharmaceuticals, ReachLocal, Tractor Supply, and RF Industries
4/14/2013, 7:06 pm from GuruFocus in Investing
According to GuruFocus Insider Data , these are the largest
CEO sales of company shares during the past week. Optimer Pharmaceuticals, Inc. ( OPTR ): Former CEO
Pedro Lichtinger Sold... Read >>
Mid-Day Market Update: Delta Tumbles On Weak Forecast, Humana Spikes Higher
4/2/2013, 12:34 pm from Benzinga in Investing, Commodities, Economy, International
Midway through trading Tuesday, the Dow traded up 0.64 percent
to 14,665.70 while the NASDAQ gained 0.68 percent to 3,261.34. The
S&P also rose, gaining 0.61 percent to 1,571.74. Top... Read >>
Optimer Posts Wider Loss - Analyst Blog
3/4/2013, 2:55 pm from Zacks.com in Investing, Business, Stocks
Optimer Pharma 's ( OPTR ) fourth quarter
2012 net loss (excluding special items) of 63 cents per share was
wider than the Zacks Consensus Estimate of a loss of 38 cents. The
company had... Read >>
Encouraging News for Cubist Pharma - Analyst Blog
3/1/2013, 5:00 pm from Zacks.com in Investing, Business, Stocks
Recently, Cubist Pharmaceuticals Inc. ( CBST ) received some
encouraging news when the US Food and Drug Administration (FDA)
designated its antibiotic candidate... Read >>
Mid-Afternoon Market Update: Dow Heading Toward All-Time High, Accretive Health Gets Blasted
2/27/2013, 3:26 pm from Benzinga in Investing, Commodities, Economy, International
Midway through trading Wednesday, the Dow traded up 1.33 percent
to 14,084.13 while the NASDAQ rose 1.46 percent to 3,176.08. The
S&P also rose, gaining 1.43 percent to 1,518.52. Index... Read >>
Mid-Day Market Update: Dollar Tree Jumps On Upbeat Profit, First Solar Tumbles
2/27/2013, 1:15 pm from Benzinga in Investing, Commodities, Economy, International
Midway through trading Wednesday, the Dow traded up 0.75 percent
to 14,004.13 while the NASDAQ rose 1.04 percent to 3,162.08. The
S&P also rose, gaining 0.91 percent to 1,510.52. Index... Read >>
Mid-Morning Market Update: Markets Up; Target Q4 Profit Falls
2/27/2013, 10:49 am from Benzinga in Investing, Commodities, Economy, International
Following the market opening Wednesday, the Dow traded up 0.22
percent to 13,931.00 while the NASDAQ rose 0.27 percent to
3,138.20. The S&P also rose, gaining 0.29 percent to
1,501.26. ... Read >>
Cubist Pharma Inks Deal - Analyst Blog
2/26/2013, 5:25 pm from Zacks.com in Investing, Business, Stocks
Cubist Pharmaceuticals Inc. ( CBST ) recently inked
an option agreement under which it has the exclusive right to buy
the privately-held Adynxx after the data readout of the... Read >>
In Line 4Q for Cubist Pharma - Analyst Blog
1/24/2013, 9:10 am from Zacks.com in Investing, Business, Stocks
Cubist Pharmaceuticals Inc. 's ( CBST ) fourth quarter
2012 earnings (excluding special items) of 48 cents per share were
in line with the Zacks Consensus Estimate and 20% below... Read >>
Optimer's Dificid Sales Look Good - Analyst Blog
1/9/2013, 6:25 pm from Zacks.com in Investing, Business, Stocks
Optimer Pharmaceuticals Inc. ( OPTR ) recently
announced its preliminary sales for the fourth quarter and full
year 2012. Optimer said that preliminary gross product sales of its... Read >>
Cubist Reports Impressive 4Q Sales - Analyst Blog
1/8/2013, 3:43 pm from Zacks.com in Investing, Business, Stocks
Cubist Pharmaceuticals Inc. 's ( CBST )
unaudited net revenues for the fourth quarter of 2012 climbed 16%
year over year to $245.9 million, driven by strong sales of its
antibiotic... Read >>